Author

Ekaterina Elsakova

Observed names: E. O. Elsakova, E. О. Elsakova, E.O. Elsakova, Elsakova, E. O., Елсакова Екатерина Олеговна

Institution: State Budget Institution of Health St. Petersburg Clinical Research Center Specialized Types of Medical Care

Observed institution: State Budget Institution of Health St. Petersburg Clinical Research Center Specialized Types of Medical Care

ORCID: 0000-0001-9552-9764

Observed ORCID: 0000-0001-9552-9764

OpenAlex ID: A5081449849

Prognostic model integrating histology, systemic inflammation, and recurrence status predicts immunotherapy response in advanced non-small-cell lung cancer patients

2025 · F. V. Moiseenko, M. A. Krasavina, et al. · Biology Direct · 7

Interconnection of Gut Microbiome and Efficacy of Immune Checkpoint Inhibitors in Inoperable Non-Small-Cell Lung Cancer

2025 · Fedor Moiseenko, Andrey Kechin, et al. · International Journal of Molecular Sciences · 2

REACT: Real-world survival outcomes with atezolizumab, bevacizumab, and chemotherapy for treatment of advanced non-squamous NSCLC

2026 · D. I. Yudin, K. K. Laktionov, et al. · Meditsinskiy sovet = Medical Council · 1

Epidermal growth factor receptor-mutated lung carcinomas with insufficient response to epidermal growth factor receptor inhibitors

2024 · Fedor Moiseenko, Ekaterina Kuligina, et al. · Future Oncology · 1

Treatment features in elderly patients with inoperable non-small cell lung cancer without driver mutations

2026 · O.S. OIvantsova, M.A. Krasavina, et al. · Practical oncology

Correlation of clinical benefit from immune checkpoints and baseline radiomic signature in inoperable NSCLC without activating mutations.

2025 · Fedor Vladimirovich Moiseenko, Marko Radulovic, et al. · Journal of Clinical Oncology

Baseline Radiomics as a Prognostic Tool for Clinical Benefit from Immune Checkpoint Inhibition in Inoperable NSCLC Without Activating Mutations

2025 · Fedor Moiseenko, Marko Radulovic, et al. · Cancers

Role of Radiotherapy in Treatment of Non-operable Egfr-mutated Nsclc

2024 · M.A. Krasavina, A.V. Kirillov, et al. · Practical oncology

Radiotherapy in Patients With Inoperable Nsclc During Therapy With Checkpoint Inhibitors

2024 · A.V. Kirillov, I.R. Agranov, et al. · Practical oncology

Validation of the 10-gene expression profile for prediction of response to checkpoint inhibitor in patients with advanced NSCLS

2024 · I.R. Agranov, A.G. Ievleva, et al. · Practical oncology

Clinical prognostic factors for the effectiveness of immunotherapy in patients with unresectable NSCLC

2024 · M.A. Krasavina, E.V. Artemieva, et al. · Practical oncology

REACT: анализ общей выживаемости в реальной клинической практике при применении атезолизумаба в сочетании с бевацизумабом и химиотерапией при распространенном неплоскоклеточном немелкоклеточном раке легкого

· Юдин Денис Иванович, Лактионов Константин Константинович, et al. · CyberLeninK (CyberLeninka)

Works count: 14

Citation count: 11

H-index: 2

I10-index: